Contineum Therapeutics (CTNM) CMO sells 3,611 shares via 10b5-1

Rhea-AI Filing Summary

Contineum Therapeutics CMO and Head of Development Tim Watkins reported option-related share movements. On March 2, 2026, he exercised stock options covering 3,611 shares of Class A common stock at $4.50 per share, increasing his option-related holdings to 249,167 shares. He then sold 3,611 shares of Class A common stock in the open market at a weighted average price of $15.0153 per share, with trades executed between $14.60 and $15.41, leaving no shares from this lot outstanding. These transactions were carried out under a Rule 10b5-1 trading plan adopted on September 23, 2025.

Insider Trade Summary

Net Seller: 3,611 shares ($54,220)

Net Sell 3 txns

Insider Watkins Tim

Role CMO & Head of Development

Sold 3,611 shs ($54K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	3,611	$0.00	--
Exercise	Class A Common Stock	3,611	$4.50	$16K
Sale	Class A Common Stock	3,611	$15.0153	$54K

Holdings After Transaction: Stock Option (right to buy) — 249,167 shares (Direct); Class A Common Stock — 3,611 shares (Direct)

Footnotes (1)

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.41, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Watkins Tim

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CMO & Head of Development

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/02/2026		M(1)		3,611	A	$4.5	3,611	D
Class A Common Stock	03/02/2026		S(1)		3,611	D	$15.0153(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.5	03/02/2026		M(1)			3,611	(3)	04/27/2035	Class A Common Stock	3,611	$0	249,167	D

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.41, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

3. One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.

	/s/ Peter Slover, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CTNM executive Tim Watkins report?

Tim Watkins exercised options for 3,611 Contineum Therapeutics shares and sold the same 3,611 shares. The sale was an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025.

How many Contineum Therapeutics (CTNM) shares did the CMO sell and at what price?

Tim Watkins sold 3,611 shares of Contineum Therapeutics Class A common stock at a weighted average price of $15.0153. Individual sale prices ranged from $14.60 to $15.41 across multiple transactions on the same trading day.

What stock options did CTNM’s CMO exercise in this Form 4 filing?

Watkins exercised stock options covering 3,611 shares of Contineum Therapeutics Class A common stock at $4.50 per share. Following the option exercise, he held 249,167 option-related shares, reflecting his remaining derivative position after this transaction.

Was the CTNM insider sale by Tim Watkins under a 10b5-1 plan?

Yes. The Form 4 notes the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Tim Watkins on September 23, 2025, indicating the sales were pre-arranged rather than discretionary trades made on that specific day.

What is the vesting schedule of the CTNM options exercised by Tim Watkins?

One-half of the option shares vested on October 28, 2025, with the remaining half vesting in 36 equal monthly installments thereafter. Continued vesting is conditioned on Tim Watkins maintaining continuous service with Contineum Therapeutics over that period.